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Background: Polymeric micelles using amphiphilic macromolecules are promising vehicles 
for antitumor targeting. In this study, we prepared anticancer agent-incorporated polymeric 
micelles using novel block copolymer.
Methods: We synthesized a block copolymer composed of dextran and poly 
(DL-lactide-co-glycolide) (DexbLG) for antitumor drug delivery. Doxorubicin was selected 
as the anticancer drug, and was incorporated into polymeric micelles by dialysis. Polymeric 
micelles were observed by transmission electron microscopy to be spherical and smaller than 
100 nm, with a narrow size distribution. The particle size of doxorubicin-incorporated polymeric 
micelles increased with increasing drug content. Higher initial drug feeding also increased the 
drug content. 
Results: During the drug-release study, an initial burst release of doxorubicin was observed 
for 10 hours, and doxorubicin was continuously released over 4 days. To investigate the in 
vitro anticancer effects of the polymeric micelles, doxorubicin-resistant HuCC-T1 cells 
were treated with a very high concentration of doxorubicin. In an antiproliferation study, the 
polymeric micelles showed higher cytotoxicity to doxorubicin-resistant HuCC-T1 cells than 
free doxorubicin, indicating that the polymeric micelles were effectively engulfed by tumor 
cells, while free doxorubicin hardly penetrated the tumor cell membrane. On confocal laser 
scanning microscopy, free doxorubicin expressed very weak fluorescence intensity, while 
the polymeric micelles expressed strong red fluorescence. Furthermore, in flow cytometric 
  analysis, fluorescence intensity of polymeric micelles was almost twice as high than with free   
doxorubicin.
Conclusion: DexbLG polymeric micelles incorporating doxorubicin are promising vehicles 
for antitumor drug targeting.
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Introduction
Dextran, a polysaccharide consisting of 1,6-, and 1,3-glucosidic linkages, is char-
acterized as a colloidal and hydrophilic substance. Due to its biocompatibility and 
immunoneutrality, dextran is extensively employed as a bioinert material in   biomedical 
science, tissue engineering, and drug delivery systems.1–5 In addition, dextran has 
  confluent moieties for chemical conjugation, ie, a hydroxyl group exists in each glucose 
unit. Therefore, dextran is frequently investigated for use as a drug carrier system for 
anticancer drugs, antidiabetic agents, antibiotics, peptides, and enzymes.1–8
Block or graft copolymers consisting of hydrophilic and lipophilic domains are 
able to form via self-assembly in an aqueous environment into polymeric micelles, 
self-assembled nanoparticles, and core-shell-type nanoparticles.9–14 Among these International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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configurations, polymeric micelles of block copolymers 
have unique   properties, ie, the hydrophobic domain of 
the copolymer forms an inner core, and the hydrophilic 
domain forms a hydrated outer shell.12 The   hydrophobic 
core is responsible for drug incorporation, and the 
hydrated outer shell guards the micelle from attack by 
the reticuloendothelial system.14 Polymeric micelles or 
core-shell-type block copolymer nanoparticles are attractive 
vehicles for solubilizing hydrophobic drugs, site-specific 
drug   delivery via active or passive targeting mechanisms, 
reducing the amount of drug administered, and avoiding 
unwanted side effects.9,14 Previously, Jeong et al reported 
that poly(DL-lactide-co-glycolide) (PLGA)-grafted dextran 
copolymer is able to form self-assembling nanoparticles 
and can be used as a vehicle to carry antitumor agents.5 The 
dextran component of the copolymer forms the hydrophilic 
outer shell, due to its aqueous solubility, while PLGA forms 
the inner core of the nanoparticle.
In this study, we synthesized block copolymers 
  composed of dextran and PLGA, and prepared polymeric 
micelles incorporating an anticancer agent for delivery. 
Because   dextran has a hydrophilic domain and PLGA has 
a hydrophobic domain, dextran-PLGA block copolymer 
(DexbLG) may have amphiphilic properties in an aqueous 
environment. We expected that DexbLG block   copolymer 
would be able to self-assemble as a core-shell-type 
polymeric micelle.   Furthermore, we prepared polymeric 
micelles using a   DexbLG block copolymer incorporating 
doxorubicin and evaluated their antitumor effects in vitro 
in   cholangiocarcinoma cells.
Methods and materials
Materials
Dextran from Leuconostoc spp (average molecular weight 
approximately 6000), triethylamine, doxorubicin HCl, 
sodium cyanoborohydride, hexamethylene diamine, and 
thiazolyl blue tetrazolium bromide (MTT) were purchased 
from Sigma Chemical Company (St Louis, MO). N,N′-
dicyclohexyl carbodiimide and N-hydroxysuccinimide   
were purchased from Aldrich Chemical Company (St Louis, 
MO). The dialysis membranes with molecular weight 
  cutoffs of 2000 g/mol and 8000 g/mol were purchased from 
Spectra/PorTM dialysis membrane (Spectrum Laboratories 
Inc, Rancho Dominguez, CA). Dichloromethane and dim-
ethyl sulfoxide were of high-performance liquid chroma-
tography grade or extra pure grade. PLGA-500 (molecular 
weight 5000 g/mol) was purchased from Wako Pure Chemi-
cals Company (Osaka, Japan).
synthesis of DexbLg block copolymer
Aminated dextran was prepared as described by   Maruyama 
et al15 with minor modifications. Dextran 180 mg was   dissolved 
in dimethyl sulfoxide, and sodium   cyanoborohydride 
(189 mg, 3 mM) was added. This mixture was stirred for 
24 hours at room temperature. Next, 10 equivalents of 
  hexamethylene diamine were added, and the mixture was 
stirred for a further 24 hours at room   temperature. The 
reactants were then introduced into the dialysis mem-
brane (molecular weight cutoff, 2000 g/mol) and dialyzed 
against deionized water for 2 days. The dialyzed solution 
was lyophilized for 3 days. The conjugation yield of amine 
was determined by 1H nuclear magnetic resonance (NMR) 
spectroscopy.16
N-hydroxysuccinimide PLGA (PLGA-NHS) was pre-
pared as follows. PLGA 500 mg was dissolved in dichlo-
romethane, and 1.5 equivalents of N,N′-dicyclohexyl 
carbodiimide and N-hydroxysuccinimide were added. This 
solution was stirred for 6 hours, and the reactants were fil-
tered to remove   byproducts. The solvent was removed under 
reduced pressure, and the solid was washed with methanol 
three times and dried under vacuum for 1 day.
For the DexLG block copolymer, 120 mg of aminated 
dextran and 100 mg of PLGA were dissolved in dry dimethyl 
sulfoxide. This solution was stirred in a nitrogen atmosphere 
for 2 days at room temperature. The reactants were then 
introduced into a dialysis membrane (molecular weight cutoff, 
8000 g/mol) and dialyzed for 2 days against deionized water 
to remove the solvent and unreacted dextran. The dialyzed 
solution was lyophilized for 3 days. After that, the white 
solid harvested was added to dichloromethane to remove 
the unreacted PLGA, and the precipitants were harvested by 
filtration. The resulting white solid was dried under vacuum 
for 3 days. The mass of final product was determined, and the 
yield of product was determined to be 89% (w/w) using the 
following equation:
  Yield of product (%, w/w) = [(weight of final product)/
(weight of aminated dextran + PLGA-NHS)] × 100.
Fluorescence study
To determine the critical micelle concentration of the 
  DexbLG block copolymer, fluorescence spectroscopy 
(  Shimadzu RF-5301 PC, Shimadzu Company Ltd, Japan) 
was performed, using pyrene as a hydrophobic probe as 
described previously.5 A polymeric micelle of DexbLG 
was prepared without incorporation of drug as follows. 
DexbLG 40 mg was dissolved in 5 mL dimethyl sul-
foxide and dialyzed against deionized water for 2 days. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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After that, the dialyzed solution was adjusted to various 
concentrations of polymeric micelles. To prepare sample 
solutions, a known amount of pyrene in acetone was 
added to each of a series of 20 mL vials, and the acetone 
was evaporated. The final concentration of pyrene was 
6.0 × 10–7 M, and 10 mL each of various concentrations 
of the polymeric micelle preparation were added and then 
heated for 3 hours at 65°C. Equilibration of the pyrene and 
polymeric micelles was achieved by allowing the solutions 
to cool overnight at room temperature. Fluorescence exci-
tation spectra were measured at an emission wavelength 
of 390 nm. Excitation and emission bandwidths were   
both 1.5 nm.
Preparation of doxorubicin-incorporated 
polymeric micelles
Polymeric micelles of the DexbLG block copolymer incor-
porating doxorubicin were prepared using the precipitation-
dialysis method.5 The DexbLG block copolymer was dissolved 
in 3 mL of dimethyl sulfoxide. Doxorubicin 5–10 mg was 
separately dissolved in 2 mL of dimethyl sulfoxide and then 
20 microliters of triethylamine was added. This solution was 
added to the DexbLG/dimethyl sulfoxide solution and stirred 
magnetically for 1 hour. This solution was dropped into 15 mL 
of deionized water over 10 minutes to form the nanoparticles. 
The solvent was removed by dialysis, ie, the nanoparticle solu-
tion was introduced into the   dialysis   membrane (molecular 
weight cutoff 8000 g/mol) and   dialyzed against distilled water 
for at least 1 day. During dialysis, the deionized water was 
exchanged at 1–2-hour intervals. The resulting solution 
was then used for analysis or lyophilized. Empty polymeric 
micelles of DexbLG block copolymer were prepared using 
the same procedure described above but without adding 
doxorubicin.
For evaluation of drug content and loading efficiency, 
5 mg of polymeric micelles incorporating doxorubicin 
were dissolved and diluted 100-fold in 10 mL of dimethyl 
  sulfoxide. The doxorubicin concentration was measured 
using an ultraviolet spectrophotometer (UV-1201, Shi-
madzu) at 479 nm. Empty polymeric micelles of DexbLG 
block copolymer were used as a blank test. The following 
equations was used to determine drug content and loading 
efficiency:
  Drug content = [(drug weight in the polymeric micelle)/
(weight of polymeric micelle)] × 100
Loading efficiency = [(Residual drug in the polymeric micelle)/ 
  (initial feeding amount of drug)] × 100.
Analysis of polymeric micelles
Characterization of the polymeric micelles was performed 
in dimethyl sulfoxide or D2O using 500 mHz 1H-NMR spec-
troscopy (500 mHz superconducting FT-NMR spectrometer, 
Varian Unity Inova 500 MHz NB High Resolution FT NMR; 
Varian Inc, Santa Clara, CA). Morphology of the polymeric 
micelles was observed using a transmission electron micro-
scope (TEM, JEOL JEM-2000 FX II, Japan). One drop of 
polymeric micelle solution containing phosphotungstic acid 
0.05% (w/w) was placed onto a carbon film coated on a cop-
per grid for TEM. Observation was done at 80 kV . The particle 
size of the polymeric micelles was measured with dynamic 
laser scattering (DLS-7000, Otsuka Electronics Company, 
Osaka, Japan). A sample solution prepared via the dialysis 
method was used to determine particle size (concentration 
1 mg/mL).
Drug-release study in vitro
The release experiment was carried out in vitro as follows. 
Polymeric micelles incorporating 3 mg of doxorubicin were 
reconstituted in 5 mL of phosphate-buffered saline (0.1 M, 
pH 7.4), and the ensuing solution was introduced into the 
dialysis membrane. Next, the dialysis membrane was placed 
in a 200 mL bottle with 95 mL of phosphate-buffered saline. 
This bottle was placed in a shaking incubator with a stirring 
speed of 100 rpm at 37°C. At specific time intervals, the media 
were sampled for analysis of drug   concentration. Afterwards, 
the whole media was replaced with fresh phosphate-buffered 
saline to prevent drug saturation. The concentration of doxo-
rubicin released into the phosphate-buffered saline was mea-
sured using the ultraviolet spectrophotometer at 479 nm.
Drug cytotoxicity test in vitro
HuCC-T1 cells (a doxorubicin-sensitive human cholang-
iocarcinoma cell line) maintained in Dulbecco’s modified 
Eagle’s medium (10% fetal bovine serum, 5% CO2 at 37°C) 
were used to evaluate the antitumor activity of the polymeric 
micelles. To prepare doxorubicin-resistant HuCC-T1 cells, 
the HuCC-T1 cells were exposed to doxorubicin for 3 hours 
and replaced with fresh medium. After that, the cells were 
incubated for 2 days in the absence of doxorubicin. This 
process was repeated three times with the same doxorubicin 
concentrations. The doxorubicin concentration was then 
gradually increased from 0.0001 µg/mL to 0.1 µg/mL over 
2 months.
Viability of the tumor cells was evaluated by an 
MTT cell proliferation assay. Doxorubicin-resistant 
HuCC-T1 cells were seeded at a density of 1 × 104 cells International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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per well in 96-well plates with 100 µL of medium before 
addition of the polymeric micelles. Next, free doxorubicin, 
polymeric micelles incorporating doxorubicin, and empty 
polymeric micelles were added to 96-well plates at 100 µL. 
Controls were treated with 0.5% v/v of dimethyl sulfoxide. 
After 2 days of incubation, 30 µL of MTT (5 mg/mL) was 
added to the 96-well plates and incubated for 4 hours. The 
formazan crystals formed were solubilized with dimethyl 
sulfoxide, and the absorbance (560 nm test/630 nm refer-
ence) was determined using an automated computer-linked 
microplate reader (Molecular Device Company, Sunnyvale, 
CA). Each measurement of drug concentration was obtained 
as the mean value of eight wells. The amount of formazan 
present is   proportional to the number of viable cells, because 
only living cells will reduce MTT to blue formazan. The 
results were expressed as a percentage of the absorbance 
present in the drug-treated cells compared with that in 
the control cells.
Observation of cells treated with polymeric 
micelles containing doxorubicin
Doxorubicin-resistant HuCC-T1 cells were seeded onto 
  cover-glass and treated with doxorubicin or polymeric micelles 
incorporating doxorubicin. After that, cells were washed with 
phosphate-buffered saline (pH 7.4, 0.1 M) and were treated 
with 4% paraformaldehyde. Next, cells were washed with 
phosphate-buffered saline and fixed by immobilization solution 
(ImmuMount, Thermo Electron Corporation, Pittsburgh, PA). 
These cells were observed with a confocal laser scanning 
microscope (CLSM, TCS-SP2; Leica, Wetzlar, Germany).
Flow cytometry analysis
To evaluate the extent of doxorubicin in the cell, doxorubicin-
resistant HuCC-T1 cells were analyzed using a flow cytom-
eter. Doxorubicin-resistant HuCC-T1 cells were seeded at a 
density of 1 × 106 cells in 6-well plates and incubated over-
night. Free doxorubicin or polymeric micelles incorporating 
doxorubicin 1 µg/mL were added and incubated for 1 hour. 
Cells were harvested and analyzed with a flow cytometer. An 
excitation wavelength at 488 nm and emission wavelength at 
522 nm were used to observe the fluorescence intensity of 
doxorubicin.
statistical analysis
Wilcoxon statistics and Student’s t-test (StatGraphics, 
  SigmaPlot) were used to assess the differences between 
  experimental groups. P , 0.05 was taken as being   statistically 
significant.
Results
characterization of DexbLg block 
copolymer
DexbLG copolymer was synthesized using aminated 
dextran and PLGA-NHS, as shown in Figure 1. Because 
polysaccharides normally have one reductive end, they 
are suitable material for block or graft copolymers. 
The reductive end of dextran was treated with sodium 
cyanoborohydride. Next, aminated dextran was prepared 
by coupling with an excess amount of hexamethylene 
diamine, as shown in Figure 1, and aminated dextran was 
purified by dialysis. The aminated dextran (dextran-NH2) 
characterized by proton NMR had intrinsic peaks at both 
dextran (3–5.5 ppm) and hexamethylene diamine (1–2.6 
ppm, data not shown). Because the protons at the 1 posi-
tion of dextran before and after their conjugation with 
hexamethylene diamine can be assumed to be similar, the 
ratio of the peak intensity of the protons at the 1 position 
of dextran to that of   hexamethylene diamine was used to 
estimate the molecular weight and conjugation yield. The 
conjugation yield of hexamethylene diamine was greater 
than 98%. Table 1 presents the characterization of dextran 
and aminated dextran. As shown in Table 1, the molecular 
weight of the dextran and aminated dextran were measured 
by gel permeation chromatography. The aminated dextran 
has a larger molecular weight than that of dextran, although 
the differences in molecular weight did not exactly reflect 
the extent of hexamethylene diamine. To conjugate PLGA 
copolymer, the carboxylic end of PLGA copolymer was 
activated at the N-hydroxysuccinimide end (PLGA-NHS). 
PLGA-NHS was mixed with aminated dextran in dry 
dimethyl sulfoxide to synthesize block copolymer. The 
synthesized DexbLG block copolymer was purified by dialy-
sis against water and precipitation in methylene   chloride. 
Because the average molecular weight of dextran was less 
than 5000 g/mol, free dextran was removed by dialysis 
against water. Because DexbLG copolymer is not soluble 
in methylene chloride, unconjugated free PLGA copolymer 
was removed by   precipitation of the synthesized block 
copolymer into methylene chloride. Figure 2 shows the 
NMR proton spectra of the resulting block copolymer. As 
shown in Figure 2, intrinsic peaks of PLGA were observed at   
1.5 ppm and 4.8 ppm, while dextran showed specific peaks at 
3–4 ppm. Table 1 shows the calculated molecular weight of 
DexbLG, indicating that molecular weight calculated from 
experimental values was not significantly different from the 
theoretical values. These results indicated that the DexbLG 
block copolymer was successfully synthesized.International Journal of Nanomedicine 2011:6
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Figure 1 synthesis schema for dextran and poly(DL-lactide-co-glycolide) block copolymer.
Table 1 characterization of DexbLg block copolymer
MW by GPC MW by 1H-NMR
Mw Mn PDIa Theoreticalb Experimentalb
Dextran 4800 4370 1.098
Dextran-Nh2 5180 4880 1.061
PLgA 4920 4780 1.029
DexbLg 10,100 9580
Notes: aPDI = Mw/Mn; btheoretical value was simply calculated from gPc data as 
follows: Mw of dextran-Nh2 + Mw of PLgA. experimental value was calculated from 
1h NMr data of PLgA and dextran.
Abbreviations: gPc, gel permeation chromatography; PDI, polydispersity index; 
PLgA,  poly(DL-lactide-co-glycolide);  DexbLg,  dextran  and  poly(DL-lactide-
  co-glycolide); MW, molecular weight; NMr, nuclear magnetic resonance imaging; 
dextran-Nh2, aminated dextran.
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characterization of polymeric micelles  
of DexbLg block copolymer
Polymeric micelles of DexbLG block copolymer were 
prepared by dialysis. Because PLGA is hydrophobic, the 
PLGA block should form the inner core of the polymeric 
micelle while the dextran domain should form the outer 
shell. Particle size was measured to investigate whether 
or not DexbLG block copolymer could form polymeric 
micelles. As shown in Figure 3, DexbLG block copolymer 
formed polymeric micelles with a narrow size distribution. 
The TEM image also demonstrates formation of polymeric 
micelles smaller than 100 nm. Empty polymeric micelles 
have an average particle size of approximately 70–80 nm, 
as shown in Table 2. To make polymeric micelles incorpo-
rating the drug, doxorubicin and DexbLG block copolymer 
were   dissolved in dimethyl sulfoxide, and the polymer solu-
tion was dropped into deionized water to form polymeric 
micelles via self-aggregation. Solvent and free drug were 
removed by dialysis against deionized water. These results 
are summarized in Table 2. As shown in Table 2, drug 
content was 7%–12% (w/w) according to the feeding ratio 
of the drug, and the higher the initial feeding of drug, the 
higher the drug content. Average particle size increased 
with an increase in drug   content, as shown in Table 2. At 
a higher drug content, the average particle size of DexbLG 
polymeric micelles increased above 160 nm.
Amphiphilic macromolecules, such as block and graft 
copolymer, are able to form polymeric micelles through a self-
assembling process in aqueous solution.5,9,13 Because dextran 
is a hydrophilic domain and PLGA is a hydrophobic domain, 
DexbLG block copolymer also has amphiphilic properties 
and can form core-shell-type polymeric micelles. A 1H-NMR 
spectra study of core-shell-type nanoparticles of DexbLG 
block copolymer is another way to demonstrate the core-
shell structure of nanoparticles. Figure 4 shows the 1H-NMR 
spectra of polymeric micelles of DexbLG block copolymer 
in D2O and dimethyl sulfoxide. When polymeric micelles 
of DexbLG block copolymer were in D2O, the specific peak 
of PLGA at 1.5 ppm disappeared, while specific peaks of 
dextran were clearly found at 3–4.7 ppm (Figure 4A). How-
ever, the 1H-NMR spectra of polymeric micelles of  DexbLG 
block copolymer revealed both peaks of dextran and PLGA 
in dimethyl sulfoxide, as shown in Figure 4B. These results 
indicated that DexbLG polymeric micelles have the typical 
structure of polymeric micelles, ie, PLGA composed of a 
hydrophobic inner core and dextran composed of a hydro-
philic outer shell. Furthermore, the self-assembling property International Journal of Nanomedicine 2011:6
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Figure 3 Transmission electron micrograph of polymeric micelles composed of 
dextran and poly(DL-lactide-co-glycolide) block copolymer.
of block copolymer is known to depend on the concentration 
of polymers in aqueous solution. To determine the critical 
micelle concentration of block copolymer, a fluorescence 
study was performed using pyrene as the hydrophobic probe. 
Figure 5A shows the fluorescence excitation spectra of pyrene 
at various concentrations of DexbLG block copolymer. The 
fluorescence intensity was increased according to the increase 
in polymer concentration, which indicates self-assembly 
of DexbLG block copolymer in water. In addition, a red 
shift was observed in the excitation spectra with increasing 
concentration of DexbLG block copolymer, indicating that 
pyrene is preferentially partitioned to the hydrophobic inner 
core of the polymeric micelle. This red shift was presented 
as the intensity ratio of I339/I336 versus log c of DexbLG block 
copolymer for the pyrene excitation spectra, as shown in 
Figure 5B. A flat region at extremely low concentration and 
a sigmoid change in the crossover region were observed. This 
result indicates that the signal change in the crossover region 
could be related to the critical micelle concentration value of 
DexbLG block copolymer. The critical micelle concentration 
values were found to be 0.00485 g/L. These results demon-
strated that the hydrophilic domain (dextran) of DexbLG 
block copolymer serves as a flexible outer shell of core-shell 
structure in aqueous solution, while the hydrophobic domain 
(PLGA) forms the solid inner core.
Figure 6 shows doxorubicin release from the polymeric 
micelles. As shown in Figure 6, the higher the drug con-
tent, the slower the drug release. An initial burst release 
of drug was observed for 10 hours, and then doxorubicin International Journal of Nanomedicine 2011:6
Table 2 characterization of DexLg polymeric micelles incorporating doxorubicin
Polymer/doxorubicin  
weight ratio (mg/mg)
Drug contents (%, w/w) Particle size (nm)
Theoretical Experimental Intensity  
(mean ± SD)
Weight  
(mean ± SD)
Number 
(mean ± SD)
40/0 – –   82.6 ± 17.3   75.6 ± 10.8   70.9 ± 8.7
40/5 11.1 7.6 122.1 ± 29.6 103.3 ± 24.0   91.4 ± 17.1
40/10 20 12.3 206.5 ± 49.7 177.5 ± 38.5 160.2 ± 27.2
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was continuously released over 4 days. These results 
indicated that hydrophobic interactions increase at higher 
drug content, and this phenomenon caused decreased drug 
release because doxorubicin is a hydrophobic anticancer 
agent.
In vitro cell cytotoxicity
To investigate the antitumor activity of free doxorubicin and 
DexbLG polymeric micelles incorporating doxorubicin, 
polymeric micelles incorporating doxorubicin were tested 
with doxorubicin-sensitive HuCC-T1 cells and doxorubicin-
resistant HuCC-T1 cells. For this test, doxorubicin-resistant 
HuCC-T1 cells were exposed to doxorubicin 0.0001 µg/mL 
to 0.1 µg/mL for several months. As shown in Figure 7A, free 
doxorubicin and polymeric micelles incorporating doxorubi-
cin showed dose-dependent growth inhibition of doxorubicin-
sensitive HuCC-T1 cells. Cell viability on exposure to free 
doxorubicin and to polymeric micelles incorporating doxo-
rubicin was not significantly different. However, polymeric 
micelles incorporating doxorubicin showed higher antitumor 
cytotoxicity against doxorubicin-resistant HuCC-T1 cells, 
as shown in Figure 7B. As shown in Figure 7C, the empty 
polymeric micelles did not significantly inhibit tumor cell 
growth. The IC50 of polymeric micelles against doxorubicin-
resistant HuCC-T1 cells was significantly lower than that for 
free doxorubicin, as shown in Figure 8B, but for doxorubicin-
sensitive cells was not significantly different. To verify these 
results, HuCC-T1 cells were observed using confocal laser 
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Figure 4 1h-NMr spectra of dextran and poly(DL-lactide-co-glycolide) polymeric micelle in D2O (A) and dimethyl sulfoxide (B).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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scanning microscopy because doxorubicin has strong red 
fluorescence, ie, tumor cells will reveal red fluorescence 
when doxorubicin enters the cell. Figure 9 supports the 
growth inhibition data. When doxorubicin-resistant cells 
were treated with free doxorubicin, HuCC-T1 cells revealed 
very weak red fluorescence intensity, while the polymeric 
micelles showed strong red fluorescence intensity. Figure 10 
also supported these results, ie, polymeric micelle treatment 
showed higher fluorescence intensity than free doxorubicin 
treatment. These results showed that DexbLG polymeric 
micelles incorporating doxorubicin are superior candidates 
for anticancer drug targeting.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 6 Drug release from polymeric micelles incorporating doxorubicin according 
to drug content.
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Figure 7 growth inhibition of doxorubicin-sensitive (A) and doxorubicin-resistant 
(B) hucc-T1 cells by treatment of polymeric micelles incorporating doxorubicin. 
1 × 104 cells were exposed to doxorubicin or polymeric micelles for 2 days. empty 
polymeric micelles were treated in a similar way to (C). empty polymeric micelles 
did not significantly inhibit cell growth rate.
Discussion
Amphiphilic macromolecules, such as block or graft copolymer 
and hydrophobized polysaccharides, can normally form self-
aggregated nanoparticles or polymeric micelles.9–11 In particu-
lar, block copolymer composed of hydrophilic and hydrophobic 
domains can form polymeric micelles via   self-assembling, 
ie, the hydrophobic block forms an inner core of the polymeric 
micelle while the hydrophilic domain forms an outer shell.10,13 
Polymeric micelles can incorporate anticancer drugs by 
hydrophobic interaction between the drug and the hydrophobic 
domain of the block copolymer.12 Given these advantages, poly-
meric micelles have been extensively investigated as delivery 
vehicles for anticancer drug targeting. Kwon et al14 reported 
that polymer micelles incorporating anticancer drugs showed 
enhanced accumulation in tumor cells and prolonged blood 
circulation times. Because polymeric micelles themselves do 
not have an active targeting moiety, the mechanism of tumor 
targeting is referred to as passive targeting by size exclusion 
or by an enhanced permeation and retention effect.17–19 Jeong 
et al10,20 also reported enhanced antitumor activity for polymeric 
micelles incorporating doxorubicin, reporting longer survival 
of mice and suppression of tumor growth.
We synthesized block copolymer composed of dextran 
(hydrophilic block) and PLGA (hydrophobic block).   Dextran 
is a well known biocompatible material, and has been widely 
used as a bioinert material and drug-carrying material. Feng 
et al3 reported that dextran plays a positive role in improving 
lymphatic drainage of liposomes. In addition, carboxymethyl 
dextrans are known to be superior vehicles for tumor   targeting.17 
Even though dextran is a superior biomaterial, it should be 
hydrophobically modified to make nanoparticulate vehicles. 
Poly(ethylene glycol) (PEG), which is frequently used as the 
hydrophilic domain of polymeric micelles,9,10,12 is also a good 
biomaterial. However, PEG has a limited functional group in its 
chain, ie, it has only one or two functional groups at the end of 
the chain.18 From this point of view, dextran has an advantage, 
in that it has a confluent functional (hydroxyl) group in its chain, 
and the hydroxyl group can be used for chemical modifica-
tion with targeting moieties, monoclonal antibodies, and drug International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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Figure 8 Ic50 of doxorubicin and polymeric micelles against doxorubicin-resistant 
hucc-T1 cells. 
Notes: *P , 0.01. The values were averaged for four independent experiments.
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Figure 9 Fluorescence images of doxorubicin-sensitive and doxorubicin-resistant huccT1 cells. huccT1 cells were exposed to doxorubicin or polymeric micelles 
(equivalent concentration of doxorubicin 1 µg/mL) for 1 hour. Fluorescence images of cells were observed with confocal laser scanning microscopy.
conjugation. Therefore, the DexbLG block copolymer could be 
considered an ideal candidate for drug targeting.
Sun et al22 also reported the synthesis of diblock copolymers 
composed of dextran and poly(ε-caprolactone) (PCL) via sul-
fide linkage. They argued that reduction-responsive biodegrad-
able micelles can be prepared using dextran-PCL copolymer. 
Susa et al23 also reported that polymeric nanoparticles 
prepared from dextran are superior vehicles for overcoming 
drug resistance in osteosarcoma. DexbLG polymeric micelles 
have spherical shapes (determined by TEM) and are smaller 
than 100 nm, as shown in Figure 3. Particle size distribution data 
also showed a narrow size distribution of DexbLG polymeric 
micelles. Furthermore, the particle sizes of DexbLG polymeric 
micelles are favorable for passive drug targeting because nano-
particles smaller than 200 nm are able to prevent attack by the 
reticuloendothelial system.24 To verify the core shell structure, 
DexbLG polymeric micelles were measured by 1H-NMR as 
shown in Figure 4. In 1H-NMR spectra, specific peaks for both 
dextran and PLGA appeared in dimethyl sulfoxide. However, 
specific peaks of PLGA disappeared in D2O, while intrinsic 
peaks of dextran still appeared. These results indicated that 
DexbLG block copolymer is able to self-aggregate as a spheri-
cal, polymeric micelle, and these compounds have a typical 
micellar structure.
HuCC-T1 cells were used to assess the potential of   DexbLG 
polymeric micelles as anticancer drug delivery vehicles. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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Figure 10 Flow cytometric analysis of doxorubicin-sensitive and doxorubicin-resistant hucc-T1 cells. huccT1 cells were exposed to doxorubicin or polymeric micelles 
(equivalent concentration of doxorubicin 1 µg/mL) for 1 hour. 1 × 106 cells were used for FAcscan analysis. Doxorubicin-sensitive cells: (A) control, (B) doxorubicin, (C) 
polymeric micelles, (D) relative fluorescence intensity. Doxorubicin-resistant cells: (E) control; (F) doxorubicin; (G) polymeric micelles; (H) relative fluorescence intensity. 
The values were averaged over four separate experiments. 
Notes: *P , 0.005; **P , 0.0001; ***P , 0.0001; ****P , 0.0001.
Prior to testing for anticancer activity,   doxorubicin-resistant 
HuCC-T1 cells were prepared. To   generate doxorubicin-
resistant HuCC-T1 cells, tumor cells were exposed to 
d  oxorubicin at a concentration of 0.0001 µg/mL, and 
replaced with fresh medium. The doxorubicin concentra-
tion gradually increased to 0.1 µg/mL. This   procedure is 
a simple way to create doxorubicin-resistant tumor cells.10 
Doxorubicin-resistant tumor cells are normally resistant to International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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penetration of doxorubicin through the cell membrane and 
resistant to doxorubicin toxicity.10 However, nanoparticles 
or polymeric micelles are known to overcome this barrier 
and efficiently deliver the drug to the tumor cell.10,23,25 
As shown in Figure 7, free doxorubicin and polymeric 
micelles containing doxorubicin dose-dependently inhibited 
growth of doxorubicin-sensitive HuCC-T1 cells. However, 
  doxorubicin-resistant cells had higher survival rates after 
doxorubicin treatment than did doxorubicin-sensitive cells. 
Even though polymeric micelles targeted to doxorubicin-
resistant cells also showed lower cytotoxicity than that of 
doxorubicin-sensitive cells (Figure 7B), they had higher 
antitumor activity than that of free doxorubicin. These 
results indicated that doxorubicin-  resistant HuCC-T1 cells 
are resistant to doxorubicin. However, polymeric micelles 
have higher potency against doxorubicin-resistant 
HuCC-T1 cells than free doxorubicin, indicating that 
polymeric micelles can penetrate the cell membrane and 
are engulfed by the cells while free doxorubicin barely pen-
etrated the cell membrane. To verify this hypothesis, doxo-
rubicin and polymeric micelle-treated HuCC-T1 cells were 
observed with confocal laser scanning microscopy because 
doxorubicin itself expresses strong red fluorescence. Con-
focal laser scanning microscopy data supported these phe-
nomena, as shown in Figure 9. Doxorubicin-sensitive cells, 
doxorubicin, and polymeric micelles showed also similar 
fluorescence images. However, fluorescence intensity for 
doxorubicin-resistant cells was very weak upon treatment 
with free doxorubicin, while polymeric micelles expressed 
strong red fluorescence. Flow cytometric measurement of 
HuCC-T1 cells further supported these phenomena, as 
shown in Figure 10. The fluorescent intensity of polymeric 
micelle treatment was almost double that of doxorubicin 
treatment. These results indicated that polymeric micelles 
of DexbLG are helpful for overcoming drug resistance of 
tumor cells. Susa et al23 also reported that dextran nanopar-
ticles encapsulating doxorubicin had a curative effect on 
multidrug resistant osteosarcoma cell lines by increasing 
the amount of drug accumulation in the nucleus via a P gly-
coprotein-independent pathway. They argued that dextran 
nanoparticles are effective for increasing apoptosis of tumor 
cells. Furthermore, Gao et al25 reported that nanoparticles 
incorporating doxorubicin using dextran/1,2-dipalmitoyl-
sn-glycero-3-phosphoethanolamine copolymer exhibited 
higher antitumor activity than that of doxorubicin itself 
against HeLa cells. We also observed the enhanced 
delivery of polymeric micelles to doxorubicin-resistant 
HuCC-T1 cells. We suggest that polymeric micelles of 
DexbLG are promising candidates for antitumor drug 
targeting.
Conclusion
DexbLG block copolymer was synthesized to make polymeric 
micelles incorporating doxorubicin. Polymeric micelles 
from DexbLG block copolymer are spherical and smaller 
than 100 nm. The particle size of the polymeric micelles 
incorporating doxorubicin increased with increasing drug 
content. Higher initial drug feeding induced higher drug con-
tent and a slower drug release rate. Drug release decreased 
with an increase of drug content. In an in vitro antiprolif-
eration study, polymeric micelles were more effective against 
doxorubicin-resistant HuCC-T1 cells than free doxorubicin, 
indicating that polymeric micelles were effectively engulfed by 
tumor cells, while free doxorubicin barely penetrated the tumor 
cell membrane. These results were supported by confocal 
laser scanning microscopic observation, ie, free doxorubicin 
treatment showed very weak fluorescence intensity while poly-
meric micelle treatment showed strong red fluorescence. Flow 
cytometric analysis of tumor cells also supported these results. 
Polymeric micelle treatment showed twice the fluorescence 
intensity as that from doxorubicin treatment. We suggest that 
DexbLG polymeric micelles incorporating doxorubicin are 
promising candidate vehicles for antitumor drug targeting.
Acknowledgment
This study was supported by a grant of the Korea Healthcare 
Technology R&D Project, Ministry for Health and Welfare, 
Republic of Korea (A091047).
Disclosure
The authors report no conflicts of interest in this work.
References
1.  Danhauser-Riedl S, Hausmann E, Schick H, et al. Phase I clinical 
and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, 
doxorubicin-OXD). Invest New Drugs. 1993;11:187–195.
2.  Du YZ, Weng Q, Yuan H, et al. Synthesis and antitumor activity of 
stearate-g-dextran micelles for intracellular doxorubicin delivery. ACS 
Nano. 2010;4:6894–6902.
3.  Feng L, Zhang L, Liu M, et al. Roles of dextrans on improving lym-
phatic drainage for liposomal drug delivery system. J Drug Target. 
2010;18:168–178.
4.  Ichinose K, Tomiyama N, Nakashima M, et al. Antitumor activity of 
dextran derivatives immobilizing platinum complex (II). Anticancer 
Drugs. 2000;11:33–38.
5.  Jeong YI, Choi KC, Song CE. Doxorubicin release from core-shell type 
nanoparticles of poly(DL-lactide-co-glycolide)-grafted dextran. Arch 
Pharm Res. 2006;29:712–719.
6.  Alahdad Z, Ramezani R, Aminlari M, et al. Preparation and properties 
of dextran sulfate-lysozyme conjugate. J Agric Food Chem. 2009;57: 
6449–6454.International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1427
Doxorubicin-incorporated polymeric micelles
  7.  Bisht S, Maitra A. Dextran-doxorubicin/chitosan nanoparticles for 
solid tumor therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 
2009;1:415–425.
  8.  Woitiski CB, Neufeld RJ, Veiga F, et al. Pharmacological effect of orally 
delivered insulin facilitated by multilayered stable nanoparticles. Eur J 
Pharm Sci. 2010;41:556–563.
  9.  Gref R, Minamitake Y, Peracchia MT, et al. Biodegradable long-
circulating polymeric nanospheres. Science. 1994;263:1600–1603.
  10.  Jeong YI, Jin SG, Kim IY, et al. Doxorubicin-incorporated nanoparticles 
composed of poly(ethylene glycol)-grafted carboxymethyl chitosan 
and antitumor activity against glioma cells in vitro. Colloids Surf B 
Biointerfaces. 2010;79:149–155.
  11.  La SB, Okano T, Kataoka K, et al. Preparation and characterization 
of the micelle-forming polymeric drug indomethacin-incorporated 
poly(ethylene oxide)-poly(beta-benzyl L-aspartate) block copolymer 
micelles. J Pharm Sci. 1996;85:85–90.
  12.  Kwon GS, Naito M, Yokoyama M, et al. Physical entrapment of adriamy-
cin in AB block copolymer micelles. Pharm Res. 1995;12:192–195.
  13.  Kwon GS, Naito M, Yokoyama M, et al. Polymeric micelles based 
on AB block copolymers of poly(ethylene oxide) and poly(β-benzyl 
L aspartate). Langmuir. 1993;9:945–949.
  14.  Kwon GS, Yokoyama M, Okano T, et al. Biodistribution of micelle-
forming polymer-drug conjugates. Pharm Res. 1993;10:970–974.
  15.  Maruyama A, Watanabe H, Ferdous A, et al. Characterization of 
interpolyelectrolyte complexes between double-stranded DNA and 
polylysine comb-type copolymers having hydrophilic side chains. 
Bioconjug Chem. 1998;9:292–299.
  16.  Perez Y, Valdivia A, Ramirez HL, Villalonga R. Improved pharmacoki-
netics properties for catalase by site-specific glycosidation with ami-
nated dextran. Macromol Rapid Commun. 2005;26(16);1304–1308.
  17.  Greish K, Nagamitsu A, Fang J, Maeda H. Copoly(styrene-maleic 
acid)-pirarubicin micelles: high tumor-targeting efficiency with little 
toxicity. Bioconjug Chem. 2005;16:230–236.
  18.  Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular perme-
ability and the EPR effect in macromolecular therapeutics: a review.   
J Control Release. 2000;65:271–284.
  19.  Noguchi Y, Wu J, Duncan R, et al. Early phase tumor accumulation 
of macromolecules: a great difference in clearance rate between tumor 
and normal tissues. Jpn J Cancer Res. 1998;89:307–314.
  20.  Jeong YI, Na HS, Cho KO, et al. Antitumor activity of adriamycin-
incorporated polymeric micelles of poly(gamma-benzyl L-glutamate)/
poly(ethylene oxide). Int J Pharm. 2009;365:150–156.
  21.  Sugahara S, Kajiki M, Kuriyama H, et al. Paclitaxel delivery 
  systems: the use of amino acid linkers in the conjugation of paclitaxel 
with carboxymethyldextran to create prodrugs. Biol Pharm Bull. 
2002;25:632–641.
  22.  Sun H, Guo B, Li X, et al. Shell-sheddable micelles based on dextran-
SS-poly(epsilon-caprolactone) diblock copolymer for efficient intracel-
lular release of doxorubicin. Biomacromolecules. 2010;11:848–854.
  23.  Susa M, Iyer AK, Ryu K, et al. Doxorubicin loaded polymeric nanopar-
ticulate delivery system to overcome drug resistance in osteosarcoma. 
BMC Cancer. 2009;9:399.
  24.  Allemann E, Gurny R, Doelker E. Drug-loaded nanoparticles – 
  preparation methods and drug targeting issues. Eur J Pharm Biopharm. 
1993;39:173–191.
  25.  Gao H, Li M, Wu Y. Novel amphiphilic dextran copolymers nanoparticles 
for delivery of doxorubicin. J Appl Polym Sci. 2010;120:2448–2458.